HCPCS Level II code J0717 denotes certolizumab pegol injectable, billed by milligram for doses administered under direct physician supervision rather than self-administration. This biologic is used for inflammatory and autoimmune conditions and is billed as a drug administration service in outpatient infusion or clinic settings. Nationally, accurate coding for high-cost biologics like certolizumab pegol affects provider reimbursement, payer medical-management workflows, and patient access to specialty therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J0717 is structured, common sites of service, and the billing context for physician-supervised administration. The publication also summarizes typical modifiers and service-line considerations, payer coverage patterns, and where to look for policy and benefit determination details.

The content provides clinical and billing context for coding teams, revenue cycle staff, and policy analysts: what the code represents, typical billing scenarios, and practical documentation touchpoints. Data not available in the input are noted where applicable; the focus remains on national implications rather than state-specific rules.